The levels of UCHL5 mRNA expression (Affymetrix ID: 229248_at) were not significantly different but were associated with poor progression free survival (PFS) (hazard ratio [HR] = 1.15; 95% confidence interval [CI] = 1.06-1.39; p = 0.15) in all patients with ovarian cancer, whereas significant difference was observed with those exhibiting TP53-mutant ovarian cancer (HR = 1.94; 95% CI = 1.31–2.86; p = 0.00071) (Figure 1D) with the inverse correlation observed in those with TP53 wild-type ovarian cancer (HR = 0.17; 95% CI = 0.04–0.71; p = 0.0062) (Figure 1E). This evidence concerns the gene UCHL5 and ovarian carcinoma.